In final analysis, J&J's underdog vaccine offers only 52.9% protection against Covid-19
It’s long been established that the single-shot vaccine produced by J&J is nowhere near as effective as two doses of the mRNA vaccine — initially viewed as a tradeoff between accessibility and efficacy.
But as scientists revealed in their final analysis of J&J’s Phase III study, the vaccine may be even less effective in the longer term.
After tracking about 39,000 participants for a median of four months (8,940 of whom had at least six months of follow-up), researchers concluded in a paper published on the New England Journal of Medicine:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.